Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM)

<i>Background and Objectives</i>: Ixazomib, used in combination with lenalidomide and dexamethasone (IRd), has shown efficacy in clinical trials for relapsed/refractory multiple myeloma (RRMM). <i>Materials and Methods</i>: This study evaluates the real-world effectiveness and safety of IRd in Croat...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Josip Batinić, Barbara Dreta, Goran Rinčić, Antonia Mrdeža, Karla Mišura Jakobac, Delfa Radić Krišto, Milan Vujčić, Mario Piršić, Željko Jonjić, Vlatka Periša, Jasminka Sinčić Petričević, Božena Coha, Hrvoje Holik, Toni Valković, Marija Stanić, Ivan Krečak, Ante Stojanović, Domagoj Sajfert, Sandra Bašić-Kinda
Format:	Artigo
Sprog:	Inglês
Udgivet:	MDPI AG 2024-11-01
Serier:	Medicina
Fag:	ixazomib lenalidomide multiple myeloma relapsed/refractory retrospective study
Online adgang:	https://www.mdpi.com/1648-9144/60/11/1905
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!